PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
0.760
-0.003 (-0.35%)
Apr 28, 2026, 4:00 PM EDT - Market closed
PharmaCyte Biotech Balance Sheet
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jan '26 Jan 31, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | 2020 - 2016 |
| Cash & Equivalents | 20.17 | 15.17 | 50.18 | 68.04 | 85.4 | 2.2 | Upgrade
|
| Short-Term Investments | 0.37 | 0.37 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 20.54 | 15.54 | 50.18 | 68.04 | 85.4 | 2.2 | Upgrade
|
| Cash Growth | 22.57% | -69.03% | -26.25% | -20.33% | 3778.14% | 146.08% | Upgrade
|
| Receivables | - | 3.7 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 0.16 | 0.22 | 0.26 | 0.11 | 0.09 | 0.07 | Upgrade
|
| Other Current Assets | - | 2.92 | - | - | - | - | Upgrade
|
| Total Current Assets | 20.7 | 22.38 | 50.44 | 68.15 | 85.49 | 2.28 | Upgrade
|
| Long-Term Investments | 22.47 | 22.47 | - | 1.57 | 1.57 | 1.57 | Upgrade
|
| Other Intangible Assets | 1.55 | 1.55 | 1.55 | 3.55 | 3.55 | 3.55 | Upgrade
|
| Other Long-Term Assets | 11.16 | 8.77 | 7.91 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Total Assets | 55.87 | 55.17 | 59.9 | 73.28 | 90.62 | 7.4 | Upgrade
|
| Accounts Payable | 1.2 | 0.4 | 0.39 | 0.13 | 0.21 | 0.17 | Upgrade
|
| Accrued Expenses | 0.35 | 0.52 | 0.74 | 0.46 | 0.5 | 0.5 | Upgrade
|
| Short-Term Debt | - | - | - | - | - | 0.05 | Upgrade
|
| Other Current Liabilities | 0.13 | 1.99 | 6.3 | - | - | - | Upgrade
|
| Total Current Liabilities | 1.68 | 2.91 | 7.42 | 0.59 | 0.7 | 0.72 | Upgrade
|
| Other Long-Term Liabilities | 14.79 | 0.36 | 12.97 | - | - | - | Upgrade
|
| Total Liabilities | 16.47 | 3.28 | 20.39 | 0.59 | 0.7 | 0.72 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 183.14 | 181.49 | 185.33 | 202.23 | 201.58 | 114.11 | Upgrade
|
| Retained Earnings | -100 | -84.97 | -115.63 | -115.96 | -111.65 | -107.41 | Upgrade
|
| Treasury Stock | -45.01 | -44.61 | -42.04 | -13.56 | - | - | Upgrade
|
| Comprehensive Income & Other | 0.4 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | Upgrade
|
| Total Common Equity | 38.53 | 51.89 | 27.65 | 72.69 | 89.92 | 6.68 | Upgrade
|
| Shareholders' Equity | 39.4 | 51.89 | 39.51 | 72.69 | 89.92 | 6.68 | Upgrade
|
| Total Liabilities & Equity | 55.87 | 55.17 | 59.9 | 73.28 | 90.62 | 7.4 | Upgrade
|
| Total Debt | - | - | - | - | - | 0.05 | Upgrade
|
| Net Cash (Debt) | 20.54 | 15.54 | 50.18 | 68.04 | 85.4 | 2.15 | Upgrade
|
| Net Cash Growth | 22.57% | -69.03% | -26.25% | -20.33% | 3869.72% | 204.54% | Upgrade
|
| Net Cash Per Share | 2.77 | 2.12 | 5.24 | 3.49 | 5.50 | 1.49 | Upgrade
|
| Filing Date Shares Outstanding | 10.74 | 6.8 | 7.71 | 8.78 | 20.75 | 1.61 | Upgrade
|
| Total Common Shares Outstanding | 10.74 | 6.8 | 8.04 | 16.79 | 20.72 | 1.59 | Upgrade
|
| Working Capital | 19.02 | 19.46 | 43.02 | 67.56 | 84.79 | 1.55 | Upgrade
|
| Book Value Per Share | 3.59 | 7.64 | 3.44 | 4.33 | 4.34 | 4.20 | Upgrade
|
| Tangible Book Value | 36.98 | 50.34 | 26.1 | 69.14 | 86.37 | 3.13 | Upgrade
|
| Tangible Book Value Per Share | 3.44 | 7.41 | 3.25 | 4.12 | 4.17 | 1.97 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.